Dogwood Therapeutics

NASDAQ: DWTX ↗$2.29 USD~$20M (microcap, August 2026) MCAP

#Chemotherapy-Induced Neuropathic Pain #Cancer Pain #Fibromyalgia #Acute Surgical Pain

Dogwood Therapeutics (formerly Virios Therapeutics, renamed October 2024) is a development-stage biotechnology company focused on first-in-class, non-opioid medicines for pain and fatigue-related disorders. Its lead candidate, Halneuron, is a highly selective sodium channel blocker in Phase 2b development for chemotherapy-induced neuropathic pain (CINP) and cancer pain, with a 12-week open-label follow-on study commenced in May 2026; IMC-1 (famciclovir + celecoxib) completed a Phase 2b trial in fibromyalgia. Founded in 2012 and headquartered in Alpharetta, Georgia.

Company Info

Sector:Biopharmaceuticals / Pain & Neuropathy

Headquarters:Alpharetta, Georgia, USA

Founded:2012

Website:www.dwtx.com/

Upcoming Milestones & Key Dates

September 1, 2026

Investor / Clinical

Virtual KOL event discussing Halneuron for chemotherapy-induced neuropathic pain

Clinical Development Pipeline

Halneuron (HAL)

Target: Highly selective sodium channel blocker

Chemotherapy-induced neuropathic pain; cancer pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

IMC-1

Target: Famciclovir + celecoxib combination

Fibromyalgia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Serpin Peptide 16

Target: Serpin peptide

Neuropathy secondary to neurotoxic chemotherapeutics

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Gregory Duncan

Chairman and Chief Executive Officer

Dr. R. Michael Gendreau, M.D., Ph.D.

Chief Medical Officer

Dr. William L. Pridgen, M.D.

Founder and Member of Scientific Advisory Board

Careers & Job Openings

No active job listings. Check back later.